Inlyta is prescribed to help slow down the progression of advanced renal cell carcinoma (kidney cancer) when other chemotherapy treatments have failed. Side effects may include fatigue, diarrhea, and nausea. This medication comes as a tablet that is taken twice a day, with 12 hours between doses. Your specific dosage will depend on how you tolerate the drug, other medications you are taking, and other factors.

What Is Inlyta?

Inlyta® (axitinib) is a prescription medication approved for the treatment of advanced renal cell carcinoma (kidney cancer) that has not responded to one or more other kidney cancer medications. It belongs to a group of medicines called kinase inhibitors.
(Click Inlyta Uses for more information on what this medication is used for, including possible off-label uses.)

Who Makes This Medication?

Inlyta is made by Pfizer, Inc.

How Does Inlyta Work?

Inlyta works by blocking receptors known as vascular endothelial growth factor (VEGF) receptors 1, 2, and 3. These receptors are found on the surface of cells, including cancer cells, and influence tumor growth and spread. By blocking VEGF receptors, Inlyta may slow down the growth and spread of cancer cells.

Clinical Effects

In a clinical study, Inlyta slowed down the progression of advanced kidney cancer two months longer than another kidney cancer medication that was given to people who had previously received other kidney cancer treatment. More specifically, Inlyta slowed down cancer progression by about 6.7 months, compared to 4.7 months with the other medication.
The Zen of Cancer Caregiving - Recharge Your Batteries!

Inlyta Medication Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2019 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.